Earnings Release
1Q26

São Paulo, Brazil, May 12, 2026 – **Dasa** (B3: DASA3, "Company") today announces its financial results for the **first quarter of 2026 (1Q26).**

Webcast

May 13, 2026

(in Portuguese with simultaneous translation into English)

2:00 p.m. (Brasília) / 1:00 p.m. (New York) / 6:00 p.m. (London)

Click **here** to access the link.

Presentation available at: dasa3.com.br

Investor Relations

ir@dasa.com.br

dasa3.com.br

Contents

Considerations on financial and operational information and disclaimers

The financial information presented here was taken from the interim accounting information ("Quarterly Information – ITR") for the quarter ended March 31, 2026, and prepared in accordance with accounting practices adopted in Brazil and the *International Financial Reporting Standards* (IFRS) issued by the *International Accounting Standards Board* (IASB) and with the standards issued by the Brazilian Securities Commission (CVM) applicable to the preparation of Quarterly Information (ITR).

To facilitate the interpretation of the results, they are presented on a consolidated basis and divided into the verticals (i) Diagnostics and (ii) Hospitals and Oncology Northeast, in addition to the analysis of the equity in results arising from 50% interest in Ímpar Serviços Hospitalares ("Rede Américas"). To reflect the Company's internal management, the information presented for each vertical includes reclassifications between costs and expenses. Data from prior periods reflect the current structure of each vertical. In addition, to provide better quarter-to-quarter comparability, the Company presents an estimate of 1Q25 as if it had operated under the same scope as 1Q26 (Diagnostics - Domestic, Hospital da Bahia and AMO Health Centers), thereby excluding from 1Q25 the hospital and oncology operations of Ímpar that became part of Rede Américas on April 1, 2025 and the divestitures of Mantris, Diagnostics - Argentina and Hospital São Domingos completed in 2025 ("1Q25 Current Scope").

To calculate the financial leverage established in connection with the debentures issued, the Company excludes from general and administrative expenses and, therefore, from EBITDA, expenses with the stock option plan, as determined in the related indentures. Accordingly, the Company uses the word "adjusted" to refer to information with the above alterations, since these reclassifications and adjustments are included in the information presented in the ITR. The calculation of EBITDA from net income is shown on page 16, which also shows the calculation of EBITDA (excluding Equity Method) to exclude the equity in results of subsidiaries arising from Rede Américas. Additionally, complete information presented here can be found in the interactive spreadsheet available on the Company's Investor Relations website, by clicking here.

The financial and operational information in this release is subject to rounding off. Consequently, total amounts shown in the tables and graphs may differ from the direct sum of the numbers that precede them. The sum of the financial information of the verticals may not correspond to Dasa's consolidated financial information, due to the elimination of transactions that occurred between segments, with no effect on EBITDA and net income.

This document may contain forward-looking statements regarding the Company's business, estimates of operating and financial results and growth prospects, as well as other future events. Forward-looking statements in this document include, but are not limited to, words such as, "anticipate," "believe," "estimate," "expect," "project," "plan," "foresee," "aim," and "seek," as well as all their variations, and other words with similar meanings, which are used to identify possible situations. Said situations involve various factors, risks or uncertainties, known or unknown, which could result in material differences between current data and any projections contained herein, and do not represent any guarantee regarding the Company's future performance.

All statements in this document are based on information and data available on the date they were made. The Company does not undertake to review or update them in any way with the emergence of new information or future events. The reader/investor is solely and exclusively responsible for any investment decision, trade or action taken based on information contained herein. The reader/investor should not consider only the information herein to make decisions concerning the trading of securities issued by the Company. For more detailed information, please refer to our Financial Statements, Reference Form and other relevant information on our Investor Relations website https://www.dasa3.com.br/.

This document does not constitute an offer to sell or a solicitation to buy any security.

Message from the Management

We concluded the first quarter of 2026 with consistent improvement in the quality of our results, reflecting the maturation of the structural initiatives implemented throughout 2025 and the consolidation of the Company's new strategic positioning.

Over the last twelve months, we conducted a significant transformation at Dasa, with organizational simplification, greater focus on core diagnostics, and discipline in capital allocation. As a result, we began 2026 with a leaner, more efficient Company and greater operational and financial predictability, prepared to continue growing profitably.

The quarter's results reflect this new operating level, with margin expansion and improved efficiency, driven mainly by productivity gains, better utilization of installed capacity, and greater discipline in managing costs and expenses. Consolidated EBITDA reached R$573 million, up 28% versus a comparable base aligned with the Company's current operating scope, with a 2.7 p.p. margin expansion, driven by 14% growth in gross revenue, also on a comparable basis.

Cash generation remains a strategic priority. In the quarter, free cash flow[1] improved by R$101 million compared with the same period of the previous year, reflecting improvements in working capital management and greater discipline in execution of investments. Considering the lower capital intensity of the Company's new scope and the typical seasonality at the beginning of the year, we maintain the expectation of robust free cash generation[1] in 2026. Consequently, we will continue reducing our leverage and strengthening our capital structure.

Additionally, Rede Américas' performance continues to progress in line with the strategic roadmap established upon the creation of the joint venture. The maturation of the hospital operations, combined with the initial capture of synergies and improved asset management, reinforces the value creation potential of this platform in the medium and long term, increasing the strategic relevance of this investment for the Company.

Currently, Dasa has a large-scale national platform, with leading brands, extensive reach, and installed capacity that enables additional growth without the need for proportional capital expansion. This positioning supports a more efficient growth model, with market share gains, margin expansion, and sustainable value creation.

For 2026, we maintain a disciplined execution agenda, focused on the diagnostics core, cost and expense control, and advancing the digitalization agenda, with an emphasis on the patient and customer experience.

We reaffirm our confidence in the Company's execution capability and its value creation potential.

THE BOARD.

[1] Operating cash generation less investments, calculated based on the Statement of Cash Flow, in the ITR, as follows: (a) cash flow generated by (used in) operating activities, plus (b) interest paid on loans, financing and debentures, less (c) payment of lease principal, and (d) additions to property, plant and equipment and intangible assets.

1Q26 Highlights

(R$ million)	1Q26	1Q25	Δ	1Q25 Current Scope[2]	Δ
Consolidated gross revenue	**2,400**	**4,213**	**-43%**	**2,104**	**14%**
Diagnostics - Domestic	2,198	1,906	15%	1,906	15%
Hospitals and Oncology Northeast	203	199	2%	199	2%
Divested operations[3]	-	2,108	n.a.	-	n.a.
Gross margin (%)	***33.5%***	***29.7%***	***3.9 p.p.***	***30.9%***	***2.6 p.p.***
Consolidated EBITDA	**573**	**708**	**-19%**	**446**	**28%**
Consolidated EBITDA margin (%)	*25.8%*	*18.5%*	*7.3 p.p.*	*23.1%*	*2.7 p.p.*
Operating cash generation[4]	**21**	**(43)**	**-148.8%**	**-**	-
Cash Conversion Cycle (days)	**60**	**106**	**-46**	**72**	**-11**
Net financial debt after acquisitions payable and advances on receivables	**5,646**	**10,551**	**-46%**	-	-
***Leverage* covenant[5]**	**2.9x**	**3.6x**	**-0.7x**	-	-

The deconsolidation of Ímpar, resulting from the formation of Rede Américas, as well as the divestitures completed during 2025, affected the comparability of the financial statements between periods. Accordingly, the highlights presented below are based on a comparable basis ("Current Scope"), reflecting solely the Company's current operating scope, excluding the effects of discontinued operations, assets sold, and businesses contributed to Rede Américas, so as to enable a clearer analysis of Dasa's recurring operating performance.

- **Diagnostic revenue increased by +15% compared to 1Q25 Current Scope**, driven by increased exam volume and expansion of premium segments, B2B, and home care.

- **Hospitals and Oncology Northeast increased by +2% in revenue vs. 1Q25 Current Scope**, reflecting the focus on profitability, operational efficiency, and better asset utilization.

- **Gross margin reached 33.5%, with an expansion of +2.6 p.p. vs. 1Q25 Current Scope,** resulting from productivity gains, better utilization of installed capacity, and fixed cost dilution.

- **Consolidated EBITDA increased by +28% vs. 1Q25 Current Scope, with a margin expansion of +2.7 p.p.** to 25.8%, reflecting the operational and financial progress of the business.

- **Cash conversion cycle reduced by 11 days vs. 1Q25 Current Scope,** with operating cash generation of R$21 million in the quarter.

- **Financial leverage decreased from 3.6x to 2.9x net debt/EBITDA,** due to EBITDA growth and disciplined capital management.

---

[2] It considers the results of the current operating scope, comprising Diagnostics - Domestic, Hospital da Bahia and AMO Health Centers.
[3] Divested operations include Mantris and Diagnostics - International (through 3Q25), Hospital São Domingos (through 4Q25), and eliminations. Additionally, starting from 2Q25, DASA stopped consolidating the results of the hospitals that were contributed for the formation of Rede Américas, and began recognizing them using the equity method.
[4] Taken from the Statement of Cash Flows, in the ITR, and calculated as follows: a) cash flow generated by (used in) operating activities plus b) interest paid on loans, financing and debentures less c) payment of lease principal.
[5] Net Debt/EBITDA (calculated as per the indentures)

Operational and Financial Performance

Diagnostics

(R$ million)	1Q26	1Q25	Δ	1Q25 Current Scope[6]	Δ
Gross revenue	**2,198**	**2,032**	**8.2%**	**1,906**	**15.3%**
Diagnostics - Domestic	2,198	1,906	15.3%	1,906	15.3%
Diagnostics - International[7]	-	126	n.a.	-	n.a.
(-) Taxes and deductions	(161)	(155)	3.6%	(153)	4.9%
Net revenue	**2,037**	**1,876**	**8.6%**	**1,752**	**16.2%**
Adjusted costs of services provided [8]	(1,248)	(1,152)	8,3%	(1,083)	15.3%
% Net revenue	*-61.3%*	*-61.4%*	*0.1p.p.*	*-61.8%*	*0.5p.p.*
Adjusted gross profit [8]	**789**	**724**	**8.9%**	**670**	**17.7%**
Gross margin	***38.7%***	***38.6%***	***0.1p.p.***	***38.2%***	***0.5p.p.***
Diagnostics - Domestic *Gross margin (%)*	*38.7%*	*38.2%*	*0.5p.p.*	*38.2%*	*0.5p.p.*
Diagnostics - International *Gross margin (%)*	-	*44.0%*	*n.a.*	-	*n.a.*

The Diagnostics division generated gross revenue of R$2.2 billion in 1Q26, up 15.3% from 1Q25 Current Scope. The result was mainly supported by increased exam volumes and the expansion of B2B channels, home-based care, and premium segment.

The volume growth reflected the expansion of the patient base, greater commercial activity, and higher utilization of installed capacity.

Net revenue reached R$2.0bn, a growth of +16.2% vs. 1Q25 Current Scope, tracking the evolution of gross revenue, with controlled variation in taxes and deductions.

Adjusted gross profit totaled R$789 million in 1Q26, an increase of 17.7% compared to the same scope and period of the previous year, while the adjusted gross margin reached 38.7%, with an expansion of 0.5 p.p. year over year. This growth is mainly due to productivity gains across the units, greater utilization of installed capacity, and continuous advances in process standardization and network optimization.

Over the last twelve months, in line with the asset optimization strategy and focus on profitability, the number of service units decreased from 849 to 838. This approach reflects the planned closure of

[6] Considers only the results of Diagnostics - Domestic.
[7] Operations in Argentina were sold at the end of 3Q25; therefore, there are no results to be reported under International in subsequent quarters.
[8] Does not include depreciation and amortization expenses.

underperforming operations, combined with the strengthening of the units with greater potential and the expansion of higher value-added services.

Regarding the patient satisfaction metric, 1Q26 NPS will not be disclosed due to methodological revisions in its measurement, related to the implementation of a new survey collection platform and the rebuilding of the response base. As a result, the metric's comparability for the quarter was reduced. After the process stabilizes, the Company will resume the recurring disclosure of NPS.

Operating indicators – Diagnostics - Domestic

Exams ('000 exams)



Average ticket[1] (R$)



[1] Average ticket = Diagnostics gross revenue / exams.

Operating units



NPS (Net Promoting Score)



Medical Innovation, Digitalization, and Operational Efficiency

Medical Innovation

In 1Q26, the Company continued expanding its portfolio of new products and services, with progress in the Genomics and Neurology areas and in the development of the infusion business, contributing to growth in strategic segments.

The period was also marked by the advancement of innovation initiatives in partnership with relevant institutions, including the Company's participation in the Abbott Pandemic Defense Coalition, focused on pathogen monitoring and the development of diagnostic solutions.

There were also initiatives conducted in women's health focusing on expanding access to diagnosis and prevention, including the provision of solutions aimed at HPV screening.

The innovation pipeline remained active throughout the quarter, with new launches aligned with the Company's main strategic areas of expertise.

Digitalization and Operational Efficiency

In 1Q26, the Company kept the advancement of its digitalization and operational efficiency agenda, with evolution in process standardization initiatives, systems integration, and modernization of the Technical Operations Units (NTOs).

Throughout the quarter, initiatives focused on automating processes, reducing TAT (response time), and optimizing the cost structure remained underway, in line with the operational excellence program. These advances contributed to productivity gains, greater efficiency in the use of installed capacity, and improvement in the margins over the period.

The digital channels continued to show consistent growth in the quarter, reflecting customers' increasing adoption of the Company's digital platforms. At the same time, the integration of artificial intelligence into digital service operations has been increasing operational efficiency, with notable gains in resolution rates through automated channels and strong adoption of the digital check-in features on the NAV platform.

The consistent evolution of digital indicators throughout the customer journey reinforces the effectiveness of the Company's digitalization strategy, contributing to greater operational efficiency, scalability, and continuous enhancement of the patient experience.

Hospitals and Oncology Northeast (HBA/AMO Health Centers/HSD[9])

(R$ million)	1Q26	1Q25	Δ	1Q25 Current Scope[10]	Δ
Gross revenue	**203**	**449**	**-54.9%**	**199**	**2.1%**
Hospitals	91	328	-72.3%	78	17.4%
Oncology	112	121	-7.7%	121	-7.7%
(-) Taxes and deductions	(17)	(41)	-59.5%	(14)	17.5%
Net revenue	**186**	**408**	**-54.4%**	**184**	**0.9%**
Adjusted costs of services provided [11]	**(128)**	**(279)**	**-54.2%**	**(132)**	**-3.5%**
% Net revenue	*-68.6%*	*-68.3%*	*0.3 p.p.*	*-71.7%*	*-3.2 p.p.*
Adjusted gross profit [11]	**58**	**129**	**-54.8%**	**52**	**12.2%**
Adjusted gross margin	*31.4%*	*31.7%*	*-0.3 p.p.*	*28.3%*	*3.2 p.p.*

Gross revenue from the Hospitals and Oncology Northeast segment totaled R$203 million in 1Q26, with growth of +2.1% compared with 1Q25, on a current-scope basis. This performance reflected new accreditations, a greater contribution from higher-complexity procedures, and the operational ramp-up of Hospital da Bahia, which posted growth of +17.4% on the same basis of comparison.

Net revenue totaled R$186 million in the quarter, an increase of +0.9% vs. 1Q25 Current Scope, tracking the evolution of gross revenue.

Adjusted gross profit reached R$58 million, with growth of +12.2% on the same comparison basis, while adjusted gross margin ended the quarter at 31.4%, with an expansion of +3.2 p.p. Costs of services provided decreased by 3.5% compared to 1Q25 Current Scope, reflecting initiatives to optimize the operational structure, manage active beds, simplify operations, and achieve efficiency gains in OPSM management.

Results for the period underscore increased operational discipline and a sharper focus on profitability, with steady efficiency gains and improved utilization of installed capacity. Occupancy rate reached 82.4% in the quarter, up 9.3 percentage points, while patient-days increased 9.5%, indicating stronger asset utilization. In parallel, the average ticket increased by 7.1% in the period, in line with the service dynamics and the increase in volume observed.

[9] Hospital São Domingos was sold on December 30, 2025.
[10] Considers only the results of Hospital da Bahia and AMO Health Centers.
[11] Does not include depreciation and amortization expenses

Operational Indicators - Hospital da Bahia

Total beds and active beds (# monthly average)



Occupancy rate (%)



Patients-day (# average of patients)



Average ticket[1] (R$)



[1] Average ticket = HBA gross revenue / patients-day.

Equity method

Rede Américas

Rede Américas represents a significant strategic investment for Dasa, with potential to value creation over the next operational cycles. The combination of scale, network density, dedicated governance, and portfolio complementarity creates conditions for the gradual capture of efficiencies, productivity gains, and improved profitability. Within this context, the quarter's performance underscores the ongoing stabilization of the asset and the potential to build a more efficient, integrated hospital platform oriented toward sustainable results.

(R$ million)	1Q26	4Q25	3Q25	2Q25	Accumulated LTM
Gross revenue	**3,378**	**3,355**	**3,412**	**3,239**	**13,384**
Taxes and deductions	(297)	(500)	(295)	(379)	(1,471)
Net revenue	**3,081**	**2,855**	**3,117**	**2,860**	**11,913**
Costs of services provided	(2,531)	(2,600)	(2,573)	(2,500)	(10,204)
Gross profit	**550**	**255**	**544**	**360**	**1,709**
Gross margin	*17.9%*	*8.9%*	*17.5%*	*12.6%*	14.3%
Selling expenses	**(54)**	**(50)**	**(128)**	**21**	**(211)**
General and administrative expenses	**(165)**	**(201)**	**(180)**	**(168)**	**(714)**
Other operating income (expenses), net	**(18)**	**9**	**222**	**(29)**	**184**
Operating profit (EBIT)	**313**	**13**	**459**	**184**	**969**
Net financial result	**(303)**	**(327)**	**(297)**	**(283)**	**(1,210)**
Income tax and social contribution	28	111	(42)	(41)	56
Net income (loss)	**38**	**(204)**	**120**	**(140)**	**(186)**
(+) Net financial result	303	327	297	283	1,210
(+) Income tax and social contribution	(28)	(111)	42	41	(56)
(+) Depreciation and amortization	125	157	152	133	567
(=) EBITDA	**438**	**169**	**611**	**318**	**1,536**
EBITDA Margin (%)	*14.2%*	*5.9%*	*19.6%*	*11.1%*	*12.9%*

In Rede Américas, financial information is presented on a sequential basis, quarter over quarter, and not in comparison with the same period of the prior year, since the *joint venture* was established in 2Q25. As the financial statements reflect the unification of distinct operations, historical information may generate material distortions and, consequently, misleading conclusions about the business's evolution.

Throughout the quarter, Rede Américas advanced a relevant agenda of operational and financial initiatives aimed at increasing efficiency, capturing synergies, and improving cash generation. Cost reduction initiatives are focused primarily on capturing synergies in procurement and optimizing structures, contributing to the gradual improvement in the profitability of operations.

Additionally, structural initiatives are underway to improve the patients' digital journey, as well as actions aimed at reviewing business terms and advancing the revenue cycle. In this context, a broad program of process review and systems standardization stands out, contributing to the reduction of disallowances, operational improvement, and the gradual reduction of the Network's average collection period.

Gross revenue totaled R$3.4 billion in the quarter, supported by the continuity of hospital operations, advances in production, improvements in bed management, and a greater share of higher-complexity procedures. Net revenue reached R$3.1 billion, reflecting the normalization of the level of taxes and deductions after the accounting adjustments made in the previous period.

Gross profit totaled R$550 million, with a gross margin of 17.9%, reflecting the recovery in profitability levels after the one-off impacts associated with the harmonization of accounting practices in 4Q25, as well as improvements in the management of costs of services provided.

EBITDA reached R$438 million in the quarter, with a margin of 14.2%, and net income totaled R$38 million in the period, of which Dasa recognizes its 50% share through the equity method.

Operational indicators

Total beds and active beds (# monthly average)



Occupancy rate (%)



Patients-day (# total of patients)



Average ticket[1] (R$)



[1] Average ticket = Rede Américsd gross revenue / patients-day.

Cash Flow and Debt

Operating cash generation totaled R$495 million in the quarter, with free cash flow of R$459 million after investments of R$36 million. Cash and cash equivalents ended the period at R$478 million and net financial debt totaled R$2.6 billion. Consequently, financial leverage (net financial debt / LTM EBITDA) decreased from 2.08x in 4Q25 to 1.66x in 1Q26.

Cash Flow

(R$ million)



Cash and cash equivalents and financial debt

(R$ millions)	1Q26	4Q25	3Q25	2Q25
Short-term debt	46	191	53	155
Long-term debt	2,987	2,983	2,980	2,976
(=) Gross financial debt	**3,033**	**3,174**	**3,033**	**3,131**
(-) Cash and cash equivalents	478	376	605	465
(=) Net financial debt	**2,555**	**2,798**	**2,428**	**2,666**
LTM EBITDA	**1,541**	**1,348**	**1,286**	**972**
Financial leverage	**1.66x**	**2.08x**	**1.89x**	**2.74x**

Leverage covenant

(R$ millions)	1Q26	4Q25	3Q25	2Q25
(=) Net debt for covenant purposes	**3,086**	**2,798**	**2,428**	**2,666**
LTM EBITDA for covenant purposes[12]	**1,066**	**1,348**	**1,286**	**972**
Leverage covenants	**2.90x**	**2.08x**	**1.89x**	**2.74x**

Starting in 1Q26, in line with the terms of the Debenture Indenture, the calculation of net debt and EBITDA for covenant purposes was updated. In the case of net debt, the inclusion of accounts payable for the acquisition of subsidiaries, as well as the financial expenses associated with them, began to be considered, while EBITDA began to reflect the pre-IFRS16 view for purposes of calculating the indicator.

[12] Until 4Q25, EBITDA for covenant purposes considered IFRS16 EBITDA, excluding expenses related to the Options Program. Starting in 1Q26, EBITDA for covenant purposes considers IFRS16 EBITDA less leases and expenses related to the Options Program.

Selling, general and administrative expenses / Other income and expenses

(R$ million)	1Q26	1Q25	Δ	1Q25 Current Scope[13]	Δ
General, administrative and selling expenses [14]	**(300)**	**(651)**	-53.9%	**(284)**	**5.8%**
General and administrative expenses	(245)	(571)	-57.1%	(243)	0.8%
Selling expenses	(24)	(35)	-30.9%	(24)	2.4%
Impairment loss on accounts receivable and effective write-offs	(31)	(46)	-31.5%	(18)	78.2%
Other operating income and expenses	**7**	**29**	**-74.8%**	**8**	**-13.2%**
Total expenses [15]	**(293)**	**(623)**	**-53.0%**	**(275)**	**6.3%**

In 1Q26, selling, general and administrative expenses totaled R$300 million, an increase of 5.8% compared to 1Q25 Current Scope. The variation mainly reflects the increase in impairment losses on accounts receivable and effective write-offs, which totaled R$31 million in the quarter, compared to R$18 million on a Current Scope base, reflecting one-off effects and focused on the receivables portfolio.

General and administrative expenses remained virtually stable compared to 1Q25 Current Scope (+0.8%), reflecting cost control and efficiency gains, while selling expenses increased by +2.4%, in line with the expansion of commercial activities.

Other operating income and expenses recorded a positive balance of R$7 million in 1Q26, in line with what was observed in 1Q25 Current Scope.

As a result, total expenses reached R$293 million in the quarter, an increase of 6.3% compared to the Current Scope base.

[13] Considers only the results of Diagnosis – Domestic, Hospital da Bahia and AMO Health Centers.
[14] Does not include Amortization and Depreciation expenses.
[15] Does not include Amortization and Depreciation expenses.

EBITDA, financial result and net result

(R$ million)	1Q26	1Q25	Δ	1Q25 Current Scope[16]	Δ
Net income (loss) for the period	**9**	**(111)**	**n.a.**	**(150)**	**n.a.**
(+) Net financial result	300	475	-36.8%	382	-21.5%
(+) IR/CSLL	12	7	82.5%	(14)	n.a.
(+) Depreciation and amortization	251	337	-25.4%	228	10.5%
EBITDA	**573**	**708**	**-19.1%**	**446**	**28.5%**
EBITDA margin	*25.8%*	*18.5%*	*7.3 p.p.*	*23.1%*	*2.7 p.p.*
(+) Equity in the results of subsidiaries	(19)	-	n.a.	-	n.a.
EBITDA (excluding Equity Method)	**554**	**708**	**-21.8%**	**446**	**24.1%**
EBITDA Margin (excluding Equity Method)	*24.9%*	*18.5%*	*6.4 p.p.*	*23.1%*	*1.8 p.p.*

Consolidated EBITDA totaled R$573 million in 1Q26, an increase of +28.5% compared to 1Q25 Current Scope, and an EBITDA margin of 25.8%, representing an expansion of +2.7 p.p. The evolution reflects the change in the Company's operating profile following the portfolio reorganization, with greater concentration in Diagnostics, combined with the capture of efficiency gains and better dilution of costs over the last few quarters.

Excluding the effects of the equity method, EBITDA reached R$554 million in the quarter, with a margin of 24.9%, growth of +24.1% vs. 1Q25 Current Scope (+1.8 pp), highlighting the evolution of profitability in the recurring operating base.

Net financial result was negative by R$300 million in 1Q26, an improvement of R$175 million compared to 1Q25, reflecting lower average debt, active liability management, and reduced financial expenses.

Income tax and social contribution expense totaled R$12 million in the quarter, reflecting the composition of taxable income under the Company's new operating profile and period-specific effects.

The quarterly result includes a non-recurring effect of approximately R$28 million, resulting from the completion of the purchase price allocation (PPA) report related to Rede Américas, which led to additional recognition (increase) of depreciation.

Net income was R$9 million in 1Q26, reversing the R$111 million loss recorded in 1Q25, reflecting improved operating performance and lower financial expenses in the period.

[16] Considers only the results of Diagnostics - Domestic, Hospital da Bahia, and AMO Health Centers.

Investments

(R$ million)	1Q26	1Q25	Δ	1Q25 Current Scope[17]	Δ
Total investments[18]	**24**	**69**	**-65.2%**	**39**	**-38.5%**
Maintenance and Expansion	11	50	-78.0%	22	-50.0%
Technology	13	19	-31.6%	17	-23.5%
Investments by segment					
Total investments	**24**	**69**	**-65.2%**	**39**	**-38.5%**
Diagnostics	10	28	-64.3%	19	-47.4%
Hospitals and Oncology Northeast	1	4	-75.0%	3	-66.7%
Corporate	13	17	-23.5%	17	-23.5%
Other	-	20	n.a.	-	n.a.

Consolidated investments totaled R$24 million in 1Q26, a 38.5% decrease compared to 1Q25 Current Scope. This reduction reflects greater discipline in capital allocation, with prioritization of higher-return projects and a focus on preserving strategic assets.

In the quarter, investments were mainly directed toward technology and modernization of operational infrastructure, totaling R$13 million, while investments in maintenance and expansion amounted to R$11 million.

[17] Considers only the results of Diagnostics - Domestic, Hospital da Bahia, and AMO Health Centers.
[18] Additions to intangible assets.

Cash Flow

(R$ million)	1Q26	1Q25	Δ
EBITDA	**573**	**708**	**-19.1%**
Rentals	(100)	(163)	38.7%
Other Non-cash Items[19]	22	184	-88.2%
IR/CSLL Paid	(23)	(69)	66.9%
Changes in Working Capital	(451)	(703)	35.9%
(=) Operating Cash Generation[20]	**21**	**(43)**	**n.a.**
Capex Cash	(15)	(53)	70.9%
(=) Free Cash Flow	**5**	**(96)**	**n.a.**

Operating cash generation improved by R$64 million in 1Q26, moving from a consumption of R$43 million in 1Q25 to a generation of R$21 million in the period. The performance was achieved even in a quarter that is seasonally more working-capital intensive, reflecting greater operational efficiency and an improvement in the cash conversion cycle. The change in working capital mainly reflected the increase in accounts receivable associated with business growth, and the payment of the installment related to the indemnity arising from the net debt adjustment provided for in the Joint Venture Agreement with Amil[21] in the amount of R$48 million.

Free cash flow improved by R$101 million in the period, changing from a use of R$96 million in 1Q25 to a generation of R$5 million in 1Q26. The improvement was driven by the recovery in operating generation, combined with lower capex spending during the period.

[19] Considers the sum of non-cash items in the Statement of cash flow, excluding the financial result and depreciation and amortization lines.
[20] Comprised of cash flow generated by operating activities, minus interest paid on loans and debentures, plus the principal portion of lease liabilities.
[21] On September 22, 2025, DASA and Amil executed an amendment to the Joint Venture Agreement to formalize the indemnification arising from the net debt adjustment between the parties. Based on the financial information as of March 31, 2025, a net amount of R$168 million was calculated, which will be paid by DASA to Ímpar in four installments over up to 24 months, adjusted based on the CDI.

Debt

Financial cash and debt position

(R$ million)	1Q26	4Q25	3Q25	2Q25	1Q25
Short-term debt	1,209	1,906	2,374	972	1,170
Long-term debt	5,988	5,984	6,280	7,200	11,736
Gross financial debt	**7,197**	**7,890**	**8,653**	**8,172**	**12,906**
(-) Cash and cash equivalents / marketable securities	1,705	2,665	2,546	1,407	3,576
Net financial debt	**5,492**	**5,225**	**6,107**	**6,765**	**9,331**
Acquisitions payable	155	185	524	509	1,049
Cash from financial advance on receivables	0	6	25	68	171
Net financial debt after acquisitions payable and advances on receivables	**5,646**	**5,416**	**6,657**	**7,342**	**10,551**
Net financial debt after acquisitions payable and advances on receivables / EBITDA	2.99x	2.67x	2.62x	2.82x	4.17 x

Gross financial debt was R$7.2 billion, with an average term of 3.5 years and average cost of CDI + 2.09% p.a. At the end of the quarter, the cash, cash equivalents, and marketable securities balance was R$1.7 billion, equivalent to 1.4x the debts totaling R$1.2 billion, which fall due by the end of 2026.

Net financial debt, after acquisitions payable and advances on receivables, ended 1Q26 at R$5.6 billion, an increase of 4.2% compared to the previous quarter, reflecting the reduction in cash during the period, primarily impacted by seasonal working capital consumption.

In terms of financial leverage, the indicator ended 1Q26 at 2.99x, below the 4.17x observed in 1Q25, maintaining a consistent downward trend. The variation compared to 4Q25 mainly reflects the removal from the LTM base of EBITDA contributions from hospitals transferred to Rede Américas and from operations divested in 2025, as shown in the “Current Scope Leverage” table below.

This calculation effect is expected to persist in the coming quarters, as LTM EBITDA begins to more fully reflect the Company’s new operating scope, with the gradual reduction in the contribution from discontinued operations and extraordinary accounting effects recorded in prior periods, until normalization in 4Q26.

Current Scope Leverage

(R$ million)	1Q26	4Q25
Net financial debt after acquisitions payable and advances on receivables	**5,646**	**5,416**
(+) EBITDA LTM Current Scope	1,828	1,728
(+) EBITDA Divested Operations + LTM Accounting Effects	63	298
(=) EBITDA LTM	1,891	2,026
Net financial debt after acquisitions payable and advances on receivables / EBITDA LTM Current Scope	**3.09x**	**3.13x**

Repayment schedule

Amortization schedule – Gross Financial Debt
(R$ million)



Leverage covenant

(R$ million)	1Q26	4Q25	3Q25	2Q25	1Q25
Net financial debt	5,492	5,225	6,107	6,765	9,331
Adj. EBITDA covenant LTM	1,910	2,053	2,564	2,631	2,559
Leverage covenant [22]	**2.88x**	**2.54x**	**2.38x**	**2.57x**	**3.65x**

The leverage ratio for covenant purposes ended 1Q26 at 2.88x. The leverage covenant remains below the limit of 4.0x set in the debt transaction indentures.

[22] Net Debt/EBITDA (calculated as per the indentures)

Ratings and Cost of debt

	Agency	Rating	Review	Cost of debt*
Dasa – Corporate	Fitch Ratings	AA(bra)	03/30/2026	-
14th Debenture*	Fitch Ratings	AA(bra)	03/30/2026	CDI + 2.20%
15th Debenture*	Fitch Ratings	AA(bra)	03/30/2026	CDI + 1.78%
16th Debenture*	Fitch Ratings	AA(bra)	04/01/2025	CDI + 1.60%
17th Debenture*	Fitch Ratings	AA(bra)	04/01/2025	CDI + 1.02%
21st Debenture*	Fitch Ratings	AA(bra)	04/01/2025	CDI + 2.12%
22nd Debenture*	Fitch Ratings	AA(bra)	03/30/2026	CDI + 3.40%
Loan 4131 - Dasa	**-**	**-**	**-**	**CDI + 3.34%**
			Weighted Average Cost	**CDI + 2.09%**

* For debentures with more than one series, the reported cost corresponds to the weighted average value among them.

Click here to read the Company’s rating reports.

ESG Agenda

Governance

Approval of Accounts – 2025 Financial Statements and Notice of Annual and Extraordinary Shareholders' Meeting (AGOE)

On March 26, 2026, the Board of Directors, unanimously and without exceptions, approved the Management Report and accounts, and the Company's financial statements for the fiscal year ended December 31, 2025, in accordance with the Statutory Audit Committee's opinion, issued on the same date, and accompanied by the independent auditors' unqualified report. The Board also authorized the disclosure of the aforementioned information in accordance with applicable laws and regulations, as well as the submission of the documents for shareholder approval at the Annual and Extraordinary Shareholders' Meeting.

At the same meeting, the Board of Directors approved the convening of the Annual and Extraordinary Shareholders' Meeting, held on April 28, 2026, exclusively in digital format, to deliberate, among other matters, on the approval of the financial statements for the fiscal year 2025, the determination of the annual overall compensation of the directors and officers for the fiscal year 2026, and related corporate matters.

Event after the reporting period – Holding of the Annual and Extraordinary Shareholders' Meeting (AGOE)

On April 28, 2026, the Company held its Annual and Extraordinary Shareholders' Meeting (the "AGOE") exclusively in digital format, with the participation of shareholders representing 85.90% of the voting share capital. At the Annual General Meeting, shareholders approved, with no qualification, the management accounts, the Management Report, and the financial statements for the fiscal year ended December 31, 2025, which recorded a loss of R$ 1,151,989,448.64, to be allocated to accumulated losses. The annual overall compensation of the officers and directors for the fiscal year 2026 was also approved in the amount of up to R$91,566,000.00, comprising fixed compensation, variable compensation and benefits, and share-based compensation.

At the Extraordinary General Meeting, the shareholders approved: (i) the Protocols and Justifications for the mergers of the companies Fernando Henriques Pinto Junior & Cia Ltda., Aliança Biotecnologia Ltda. and Instituto de Hematologia de São José do Rio Preto Ltda. into the Company; (ii) the ratification of the engagement of Apsis Consultoria e Avaliações Ltda. as the independent appraisal firm; (iii) the respective appraisal reports at book value; and (iv) the amendment and consolidation of the Bylaws, aimed at improving corporate governance practices. The approved mergers are part of the Company's corporate simplification and operational optimization strategy, and the effectiveness and consummation of the transactions remain subject to the fulfillment of the conditions precedent set forth in the respective protocols, with an effective date expected on May 4, 2026. Management was also authorized to take all actions necessary to implement the resolutions approved at the Shareholders' Meeting.

The filed documents are available on the Company's Investors Relations website (click here).

Social

Diversity, Equity, and Inclusion

In the first quarter of 2026, the Company continued advancing its Diversity, Equity and Inclusion agenda, with a focus on initiatives aimed at expanding opportunities, strengthening an inclusive culture, and engaging teams around the topic.

During the period, the Dasa Indica | People with Disabilities Program was launched, an initiative that encourages internal referrals for affirmative-action roles through employee participation. The initiative broadens access to opportunities for people with disabilities and reinforces the Company's commitment to workplace inclusion, while also engaging teams in building a more diverse and representative environment.

In the context of International Women's Day, we continue with awareness and engagement initiatives focused on gender equity. One of the key initiatives was a thematic livestream with Ana Carolina Côrte, Chief Medical Officer of the Brazilian Olympic Committee, covering subjects such as professional trajectory, women's leadership, and representation, thereby deepening internal discussion on the issue.

In this context, the "Delas para Elas" program was also developed, bringing together 30 women executives in meetings with employees at different stages of their careers. The initiative involved one-on-one sessions between the female executives and employees, focusing on the exchange of experiences, broadening of perspectives, and professional guidance, contributing to the development and strengthening of women's presence in the Company.

The initiatives in the period reinforce the Company's commitment to valuing diversity in its different dimensions, promoting a more inclusive, equitable work environment aligned with its institutional values.

Exhibits

Income Statement

(R$ thousand)	1Q26	1Q25	Δ
Net operating revenue	**2,222,829**	**3,826,272**	**-41.9%**
Costs of services provided	(1,477,465)	(2,691,179)	-45.1%
Gross profit	**745,364**	**1,135,093**	**-34.3%**
General and administrative expenses	(394,481)	(712,274)	-44.6%
Selling expenses	(24,154)	(34,935)	-30.9%
Impairment loss on accounts receivable	(31,291)	(45,690)	-31.5%
Other expenses and income, net	7,223	28,704	-74.8%
Equity in results of subsidiaries	18,855	-	-
Profit (loss) before net financial expenses and income tax and social contribution	**321,516**	**370,898**	**-13.3%**
Financial income	121,217	104,695	15.8%
Financial expenses	(421,174)	(579,524)	-27.3%
Financial income (expenses), net	**(299,957)**	**(474,829)**	**-36.8%**
Profit (loss) before income tax and social contribution	**21,559**	**(103,931)**	**-120.7%**
Current income tax and social contribution	(43,253)	(59,329)	-27.1%
Deferred income tax and social contribution	30,913	52,569	-41.2%
Profit (loss) for the period from continuing operations	**9,219**	**(110,691)**	**-108.3%**

Balance Sheet

(R$ thousand)	03/31/2026	12/31/2025	Δ
Current assets			
Cash and cash equivalents	1,704,455	2,665,170	-36.0%
Financial investments	559	-	-
Trade accounts receivable	2,376,754	2,101,307	13.1%
Inventories	175,033	190,372	-8.1%
Taxes recoverable	487,191	428,680	13.6%
Other assets	279,050	268,729	3.8%
Total current assets	**5,023,042**	**5,654,258**	**-11.2%**
Non-current assets			
Long-term assets			
Restricted financial investments	2,253	2,301	-2.1%
Derivative financial instruments	9,226	9,568	-3.6%
Trade accounts receivable	10,895	14,141	-23.0%
Taxes recoverable	35,784	29,010	23.4%
Court deposits	50,750	42,496	19.4%
Deferred taxes	916,143	885,197	3.5%
Other assets	206,073	99,175	1.3%
Total long-term assets	**1,186,144**	**1,186,144**	**3.8%**
Investments in jointly-controlled entity	4,651,708	4,669,403	-0.4%
Other investments	4,243	4,243	0.0%
Fixed assets	1,539,379	1,573,372	-2.2%
Right of use assets	1,067,841	1,089,996	-2.0%
Intangible assets	4,297,174	4,384,819	-2.0%
Total non-current assets	**12,791,469**	**12,907,977**	**-0.9%**
Total assets	**17,814,511**	**18,562,235**	**-4.0%**
Current liabilities			
Suppliers	801,263	866,239	-7.5%
Loans and financing	6,915	19,645	-64.8%
Debentures	1,197,946	1,882,414	-36.4%
Income tax and social contribution payable	36,782	9,455	289.0%
Social and labor liabilities	549,256	501,817	9.5%
Taxes payable	140,474	130,722	7.5%
Accounts payable for acquisition of subsidiaries	274,841	265,015	3.7%
Derivative financial instruments	4,216	4,208	0.2%
Lease liabilities	486,314	454,105	7.1%
Other accounts payable and provisions	355,586	429,602	-17.2%
Total current liabilities	**3,853,593**	**4,563,222**	**-7.5%**
Non-current liabilities			
Suppliers	22,901	22,901	0.0%
Loans and financing	248,419	248,249	0.1%
Debentures	5,489,587	5,484,214	0.1%
Taxes payable	10,002	9,648	3.7%

Accounts payable for acquisition of subsidiaries	24,445	24,543	-0.4%
Derivative financial instruments	258,783	261,243	-0.9%
Provisions for tax, labor and civil matters	243,189	241,301	0.8%
Lease liabilities	708,056	753,299	-6.0%
Deferred taxes	9,139	9,120	0.2%
Other accounts payable and provisions	50,177	51,490	-2.6%
Total non-current liabilities	**7,064,698**	**7,106,008**	**-0.6%**
Total liabilities	**10,918,291**	**11,669,230**	**-6.4%**
Equity			
Share capital	19,539,062	19,539,062	0.0%
Capital reserves	1,035,192	1,032,423	0.3%
Treasury stock	(79,136)	(79,136)	0.0%
Equity valuation adjustments	(9,596,034)	(9,596,475)	0.0%
Accumulated losses	(4,032,677)	(4,030,758)	0.0%
Equity attributable to shareholders of Dasa	**6,866,407**	**6,865,116**	**0.0%**
Non-controlling interests in subsidiaries	29,813	27,889	6.9%
Total equity	**6,896,220**	**6,893,005**	**0.0%**
Total liabilities and equity	**17,814,511**	**18,562,235**	**-4.0%**

Statement of Cash Flow

(R$ thousand)	1Q26	1Q25	Δ
Cash flow from operating activities			
Profit (loss) before income tax and social contribution	**21,559**	**(103,931)**	**-120.7%**
Items not affecting cash and cash equivalents:			
Depreciation and amortization	251,498	337,354	-25.4%
Provisions for tax, social security, labor and civil matters	2,441	125,993	-98.1%
Interest accrual and foreign exchange variation on loans and financing, fixed assets, intangible assets and accounts payable for the acquisition of subsidiaries	278,617	458,899	-39.3%
Result from derivative financial instruments	(2,110)	(34,900)	-94.0%
Result from the disposal of investments, fixed assets, intangible assets and right-of-use assets	(1,675)	8,596	-119.5%
Share-based payment update	2,769	5,066	-45.3%
Equity in results of subsidiaries	(18,855)	-	-
Expected losses (gains) due to allowance for doubtful accounts	17,472	3,079	467.5%
Provision (reversal) for disallowances	872	24,316	-96.4%
Accrued interest and foreign exchange variation on financial investments	-	(786)	-
Provision (reversal) for inventory loss	1,121	464	141.6%
Interest adjustment on lease liability	40,982	68,214	-39.9%
(Increase) decrease in assets			
Accounts receivable	(290,545)	(409,402)	-29.0%
Inventories	14,218	(20,916)	-168.0%
Other current assets	(71,474)	(106,427)	-32.8%
Other non-current assets	(13,656)	86,051	-115.9%
Increase (decrease) in liabilities			
Suppliers	(73,689)	(95,853)	-23.1%
Accounts payable and provisions	(6,601)	(157,519)	-95.8%
Discontinued operation	(8,871)	1,324	-770.0%
	144,073	**189,622**	**-24.0%**
Interest paid on loans and financing and debentures	(154,280)	(159,417)	-3.2%
Payment of lease interest	(40,982)	(68,214)	-39.9%
Income tax and social contribution paid	(22,882)	(69,117)	-66.9%
Cash flow generated by (used in) operating activities	**(74,071)**	**(107,126)**	**-30.9%**
Cash flow from investing activities			
Acquisition of fixed assets	(15,436)	(45,653)	-66.2%
Acquisition of intangible assets	(29)	(7,474)	-99.6%
Amount received from the disposal of fixed assets and intangible assets	896	23	3795.7%
Financial investments	(559)	(99,373)	-99.4%
Withdrawal from financial investments	-	111,734	-
Cash flow used in investing activities	**(15,128)**	**(40,743)**	**-62.9%**
Funds obtained from loans, financing, and debentures	-	3,000,000	-
Payment of loans, financing, and debentures	(811,116)	(1,007,831)	-19.5%
Dividends and interest on equity paid	(457)	(622)	-26.5%
Payments of accounts payable for acquisitions of subsidiaries	(682)	(53,806)	-98.7%

Payment of lease principal	(59,261)	(95,206)	-37.8%
Cash flow generated by (used in) financing activities	**(871,516)**	**1,842,535**	**-147.3%**
Increase (decrease) in cash and cash equivalents	**(960,715)**	**1,694,666**	**-156.7%**
Balance of cash and cash equivalents:			
At the beginning of the period	2,665,170	1,742,762	52.9%
At the end of the period	1,704,455	3,437,428	-50.4%
	(960,715)	**1,694,666**	**-156.7%**